Navigation Links
Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets
Date:4/14/2009

URBANA, Ill., April 14 /PRNewswire/ -- Health Alliance Medical Plans, Inc., a leading provider-sponsored health insurer, covering more than 310,000 members in Illinois and Iowa, has announced an innovative Fracture Protection Pilot Program, in cooperation with the Alliance for Better Bone Health, the makers of Actonel, a prescription drug for the treatment and prevention of postmenopausal osteoporosis. Through the program, the Alliance for Better Bone Health will cover the average medical expenses incurred to treat certain non-spinal osteoporotic fractures in women correctly taking Actonel, by proportionally reducing Health Alliance's cost of purchasing Actonel.

This Fracture Protection Program puts Health Alliance at the forefront of the nation's healthcare policy providers. This new pilot program is for commercial plans and focuses on the effectiveness of the drug, rather than just the cost.

Jeff Ingrum, Health Alliance CEO, praises the new agreement. "At Health Alliance, we have a variety of member outreach initiatives, all meant to improve outcomes and control costs for our customers. The Alliance for Better Bone Health is backing up the efficacy of Actonel to help prevent non-spinal fractures with a concept that has been talked about for years by pharmaceutical manufacturers, but few have ever executed. To the best of our knowledge, no other osteoporosis drugs are offering a similar medical outcome reimbursement."

Under the Actonel Fracture Protection Program, the Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi-aventis) will help offset equivalent costs of a covered non-spinal fracture to Health Alliance for eligible members correctly taking Actonel prior to the fracture.

The pilot program could lower insurance costs for Health Alliance, which in turn, could be passed along to subscribers in the future.

Actonel is the only once-a-month osteoporosis pill approved to help prevent both spinal and non-spinal fractures in postmenopausal women. Non-spinal fractures were measured as a group, not separately.

Dan Hecht, General Manager for P&G Pharmaceuticals, North America, said, "Because we're confident in the clinically proven fracture efficacy of Actonel, we're willing to stand behind our product with this unique fracture reimbursement program."

"The Alliance for Better Bone Health and Health Alliance care deeply about the medical outcomes their patients get as a result of taking products like Actonel," said Brent Ragans, Vice President, General Therapeutics, for sanofi-aventis. "We're very pleased to be working with the Health Alliance."

About Osteoporosis

Osteoporosis is a silent disease that affects millions of postmenopausal women, making their bones weak and more likely to fracture over time. In fact, in the U.S. today, 8 million women are estimated to already have osteoporosis, and almost 27 million more are estimated to have low bone mass, placing them at increased risk for fracture. Each year the incidence of osteoporosis-related fractures is greater than the incidence of heart attacks, strokes, and breast cancer combined. The good news is that there are prescription medications available that effectively reduce both vertebral and nonvertebral fracture risk.

About Actonel (risedronate sodium) Tablets

Actonel is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min).

Bisphosphonates, including Actonel, may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcers. Actonel should be taken according to the dosing instructions to minimize the risk of these events. Patients should discontinue use if new or worsening symptoms occur.

There have been reports of severe and occasionally incapacitating bone, joint and/or muscle pain in patients taking bisphosphonates. Rare occurrences of osteonecrosis, primarily of the jaw (ONJ), have been reported in patients treated with bisphosphonates. Most cases were reported in cancer patients receiving intravenous bisphosphonates, but some have been in patients treated orally for osteoporosis. Most cases were reported in patients undergoing dental procedures such as tooth extraction.

Most common adverse reactions reported in >10% of patients treated with ACTONEL and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia. Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions), and eye inflammation (iritis, uveitis) have been reported rarely.

Please see full prescribing information for Actonel(R) for additional safety information. For a copy of the full prescribing information for Actonel visit the Actonel Web site at www.actonel.com

About Health Alliance Medical Plans, Inc.

Health Alliance Medical Plans is a leading provider-sponsored health insurer in the Midwest, providing health care coverage to more than 310,000 members in Illinois and Iowa. Health Alliance is named one of 'America's Best Health Plans' in the 2008 U.S. News and World Report and National Committee for Quality Assurance (NCQA) rankings of commercial and Medicare health plans. Additionally, in recognition of its exceptional commitment to quality, Health Alliance has maintained the highest accreditation possible from NCQA for its HMO, POS and Medicare HMO plans since 1997.

About the Alliance for Better Bone Health

The Alliance for Better Bone Health was formed in May 1997 to promote bone health and disease awareness through numerous activities to support physicians and patients around the globe. It is a collaboration between Procter & Gamble Pharmaceuticals and sanofi-aventis U.S.


'/>"/>
SOURCE Health Alliance Medical Plans, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Health Experts Launch Bipartisan Coalition to Fight Chronic Disease
2. Mahone Hires Connie Garrison as Head of Healthcare Staffing Services
3. AARP/Walgreens Wellness Tour to Provide Free Health Screenings and Services
4. Pacer Health Corporation Successfully Completes Assignment of $11.7 Million in Convertible Debentures
5. Womens Health Advocates To Moms: We Can Beat Cervical Cancer!
6. Broadlane Helps Health System Realize Significant Financial and Operational Improvements
7. How To Get Fit By Summer; Life123 Helps Feed Your Mind and Improve Your Health
8. got milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Marina Del Rey Middle School in Los Angeles
9. Beyond Reform - Modernizing the Health Care System
10. Compirion Healthcare Consulting Generates a 40:1 Return on Investment at the Medical Center of Central Georgia
11. Review Confirms Links Between Diet, Heart Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... offices in Houma, LA, celebrates the beginning of a new charity campaign. As ... assist Court Appointed Special Advocates (CASA). In the belief that children deserve a ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Echo Therapeutics, ... device company focused on non-invasive continuous glucose ... today announced that it will host a ... 17, 2015 at 9:00 a.m. Eastern Time ... its corporate strategy, advancements in its CGM ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Global Skin Protective Equipment Market 2016-2020" ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
Breaking Medicine Technology: